KORU Medical Systems, Inc. (KRMD)
KRMDNASDAQ-CMMedical/Dental Instruments
$3.69
-0.2000 (-5.14%) today
Closed, Nov 12, 4:00 PM ET
- Market cap
- $160.05m
- P/E
- –
- EPS, last 4 quarters
- $-0.0200
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.86 to $6.61
- Average volume
- –
- Previous close
- $3.89
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $5.25, +42.3% from here
Earnings
next estimate $0.00000000Next report
Dec 2025
+50.0%
Mar 2026
0.0%
Jun 2026
+150.0%
Sep 2026
–
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $10.89m | $11.77m | $12.04m | $11.57m |
| Gross profit | $6.82m | $7.23m | $7.85m | $7.55m |
| Operating income | -$547.0k | -$865.0k | $627.0k | $187.0k |
| Net income | -$487.0k | -$807.0k | $252.0k | $218.0k |
Last four quarters: revenue $46.27m, margin -1.8%, free cash flow -$387.0k
News
8 latest- Biotech And Healthcare Stocks Move Higher: KRMD, CARL Surge 24%, AZTA Climbs 23% RTTNews · 1 day ago
- KORU Medical (KRMD) Q3 2026 Earnings Call TranscriptThe Motley Fool · 2 days ago
- What KORU Medical Systems (KRMD) Said on Its Q3 Earnings CallMarketBeat · 2 days ago
- Reasons to Retain Doximity Stock in Your Portfolio for NowZacks · Oct 5, 2026
- KORU (KRMD) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 12, 2026
- KORU Medical Systems Q2 Earnings Call HighlightsMarketBeat · Aug 5, 2026
- KORU Medical Systems, Inc. (KRMD) Q2 Earnings and Revenues Beat EstimatesZacks · Aug 5, 2026
- KORU Medical Systems Q1 Net Loss Narrows On Revenue Growth; Reaffirms FY26 Guidance; Stock Up RTTNews · May 7, 2026
The company
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the 'Freedom System') currently includes the Freedom60 and FreedomEDGE Syringe Infusion Drivers, Precision Flow Rate Tubing and HigH-Flo Subcutaneous Safety Needle Sets. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Service and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- korumedical.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.